Top

BMC Neurology

Published in:

Open Access 01-12-2022 | Alzheimer's Disease | Research

Caspase-1 variant influencing CSF tau and FDG PET levels in non-demented elders from the ADNI cohort

Authors: Yi Liu, Meng-Shan Tan, Zuo-Teng Wang, Wei Xu, Lan Tan

Published in: BMC Neurology | Issue 1/2022

Abstract

Background

Genetic variations in the inflammatory Caspase-1 gene have been shown associated with cognitive function in elderly individuals and in predisposition to Alzheimer’s disease (AD), but its detailed mechanism before the typical AD onset was still unclear. Our current study evaluated the impact of Caspase-1 common variant rs554344 on the pathological processes of brain amyloidosis, tauopathy, and neurodegeneration.

Methods

Data used in our study were obtained from the Alzheimer’s Disease Neuroimaging Initiative (ADNI) cohort. We examined the relationship between Caspase-1 rs554344 allele carrier status with AD-related cerebrospinal fluid (CSF), PET, and MRI measures at baseline by using a multiple linear regression model. We also analyzed the longitudinal effects of this variant on the change rates of CSF biomarkers and imaging data using a mixed effect model.

Results

We found that Caspase-1 variant was significantly associated with FDG PET levels and CSF t-tau levels at baseline in total non-demented elderly group, and especially in mild cognitive impairment (MCI) subgroup. In addition, this variant was also detected associated with CSF p-tau levels in MCI subgroup. The mediation analysis showed that CSF p-tau partially mediated the association between Caspase-1 variant and CSF t-tau levels, accounting for 80% of the total effect.

Conclusions

Our study indicated a potential role of Caspase-1 variant in influencing cognitive function might through changing tau related-neurodegeneration process.

Available only for authorised users

Heppner FL, Ransohoff RM, Becher B. Immune attack: the role of inflammation in Alzheimer disease. Nat Rev Neurosci. 2015;16(6):358–72. https://doi.org/10.1038/nrn3880.CrossRefPubMed

Labzin LI, Heneka MT, Latz E. Innate immunity and Neurodegeneration. Annu Rev Med. 2018;69:437–49. https://doi.org/10.1146/annurev-med-050715-104343.CrossRefPubMed

Heneka MT, Kummer MP, Stutz A, Delekate A, Schwartz S, Vieira-Saecker A, et al. NLRP3 is activated in Alzheimer's disease and contributes to pathology in APP/PS1 mice. Nature. 2013;493(7434):674–8. https://doi.org/10.1038/nature11729.CrossRefPubMed

Ising C, Venegas C, Zhang S, Scheiblich H, Schmidt SV, Vieira-Saecker A, et al. NLRP3 inflammasome activation drives tau pathology. Nature. 2019;575(7784):669–73. https://doi.org/10.1038/s41586-019-1769-z.CrossRefPubMedPubMedCentral

Liu L, Chan C. The role of inflammasome in Alzheimer's disease. Ageing Res Rev. 2014;15:6–15. https://doi.org/10.1016/j.arr.2013.12.007.CrossRefPubMed

Saresella M, La Rosa F, Piancone F, Zoppis M, Marventano I, Calabrese E, et al. The NLRP3 and NLRP1 inflammasomes are activated in Alzheimer's disease. Mol Neurodegener. 2016;11:23. https://doi.org/10.1186/s13024-016-0088-1.CrossRefPubMedPubMedCentral

Tan MS, Yu JT, Jiang T, Zhu XC, Tan L. The NLRP3 inflammasome in Alzheimer's disease. Mol Neurobiol. 2013;48(3):875–82. https://doi.org/10.1007/s12035-013-8475-x.CrossRefPubMed

Dinarello CA. Interleukin-1 in the pathogenesis and treatment of inflammatory diseases. Blood. 2011;117(14):3720–32. https://doi.org/10.1182/blood-2010-07-273417.CrossRefPubMedPubMedCentral

Ding J, Wang K, Liu W, She Y, Sun Q, Shi J, et al. Pore-forming activity and structural autoinhibition of the gasdermin family. Nature. 2016;535(7610):111–6. https://doi.org/10.1038/nature18590.CrossRefPubMed

10.

Trompet S, de Craen AJ, Slagboom P, Shepherd J, Blauw GJ, Murphy MB, et al. Genetic variation in the interleukin-1 beta-converting enzyme associates with cognitive function. The PROSPER study. Brain. 2008;131(Pt 4):1069–77. https://doi.org/10.1093/brain/awn023.CrossRefPubMed

11.

Pozueta A, Vázquez-Higuera JL, Sánchez-Juan P, Rodríguez-Rodríguez E, Sánchez-Quintana C, Mateo I, et al. Genetic variation in caspase-1 as predictor of accelerated progression from mild cognitive impairment to Alzheimer's disease. J Neurol. 2011;258(8):1538–9. https://doi.org/10.1007/s00415-011-5935-y.CrossRefPubMed

12.

Sperling RA, Aisen PS, Beckett LA, Bennett DA, Craft S, Fagan AM, et al. Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dementia. 2011;7(3):280–92. https://doi.org/10.1016/j.jalz.2011.03.003.CrossRef

13.

Jack CR Jr, Bennett DA, Blennow K, Carrillo MC, Dunn B, Haeberlein SB, et al. NIA-AA research framework: toward a biological definition of Alzheimer's disease. Alzheimers Dement. 2018;14(4):535–62. https://doi.org/10.1016/j.jalz.2018.02.018.CrossRefPubMedPubMedCentral

14.

Mueller SG, Weiner MW, Thal LJ, Petersen RC, Jack CR, Jagust W, et al. Ways toward an early diagnosis in Alzheimer's disease: the Alzheimer's disease neuroimaging initiative (ADNI). Alzheimers Dementia. 2005;1(1):55–66. https://doi.org/10.1016/j.jalz.2005.06.003.CrossRef

15.

Olsson A, Vanderstichele H, Andreasen N, De Meyer G, Wallin A, Holmberg B, et al. Simultaneous measurement of beta-amyloid(1-42), total tau, and phosphorylated tau (Thr181) in cerebrospinal fluid by the xMAP technology. Clin Chem. 2005;51(2):336–45. https://doi.org/10.1373/clinchem.2004.039347.CrossRefPubMed

16.

Tan MS, Wang P, Ma FC, Li JQ, Tan CC, Yu JT, et al. Common variant in PLD3 influencing cerebrospinal fluid Total tau levels and hippocampal volumes in mild cognitive impairment patients from the ADNI cohort. J Alzheimers Dis. 2018;65(3):871–6. https://doi.org/10.3233/jad-180431.CrossRefPubMed

17.

Tan MS, Yang YX, Xu W, Wang HF, Tan L, Zuo CT, et al. Associations of Alzheimer's disease risk variants with gene expression, amyloidosis, tauopathy, and neurodegeneration. Alzheimers Res Ther. 2021;13:1:15. https://doi.org/10.1186/s13195-020-00755-7.CrossRef

18.

Yu JT, Li JQ, Suckling J, Feng L, Pan A, Wang YJ, et al. Frequency and longitudinal clinical outcomes of Alzheimer's AT(N) biomarker profiles: a longitudinal study. Alzheimers Dementia. 2019;15(9):1208–17. https://doi.org/10.1016/j.jalz.2019.05.006.CrossRef

19.

Jack CR Jr, Bernstein MA, Fox NC, Thompson P, Alexander G, Harvey D, et al. The Alzheimer's disease neuroimaging initiative (ADNI): MRI methods. J Magn Reson Imaging. 2008;27(4):685–91. https://doi.org/10.1002/jmri.21049.CrossRefPubMedPubMedCentral

20.

Baron RM, Kenny DA. The moderator-mediator variable distinction in social psychological research: conceptual, strategic, and statistical considerations. J Pers Soc Psychol. 1986;51(6):1173–82. https://doi.org/10.1037//0022-3514.51.6.1173.CrossRefPubMed

21.

Halle A, Hornung V, Petzold GC, Stewart CR, Monks BG, Reinheckel T, et al. The NALP3 inflammasome is involved in the innate immune response to amyloid-beta. Nat Immunol. 2008;9(8):857–65. https://doi.org/10.1038/ni.1636.CrossRefPubMedPubMedCentral

22.

Tan MS, Tan L, Jiang T, Zhu XC, Wang HF, Jia CD, et al. Amyloid-β induces NLRP1-dependent neuronal pyroptosis in models of Alzheimer's disease. Cell Death Dis. 2014;5(8):e1382. https://doi.org/10.1038/cddis.2014.348.CrossRefPubMedPubMedCentral

23.

Álvarez-Arellano L, Pedraza-Escalona M, Blanco-Ayala T, Camacho-Concha N, Cortés-Mendoza J, Pérez-Martínez L, et al. Autophagy impairment by caspase-1-dependent inflammation mediates memory loss in response to β-amyloid peptide accumulation. J Neurosci Res. 2018;96(2):234–46. https://doi.org/10.1002/jnr.24130.CrossRefPubMed

24.

Flores J, Noël A, Foveau B, Beauchet O, LeBlanc AC. Pre-symptomatic Caspase-1 inhibitor delays cognitive decline in a mouse model of Alzheimer disease and aging. Nat Commun. 2020;11:1:4571. https://doi.org/10.1038/s41467-020-18405-9.CrossRefPubMed

25.

Gao Y, Tan L, Yu JT, Tan L. Tau in Alzheimer's disease: mechanisms and therapeutic strategies. Curr Alzheimer Res. 2018;15(3):283–300. https://doi.org/10.2174/1567205014666170417111859.CrossRefPubMed

26.

Giannakopoulos P, Herrmann FR, Bussière T, Bouras C, Kövari E, Perl DP, et al. Tangle and neuron numbers, but not amyloid load, predict cognitive status in Alzheimer's disease. Neurology. 2003;60(9):1495–500. https://doi.org/10.1212/01.wnl.0000063311.58879.01.CrossRefPubMed

27.

Thawkar BS, Kaur G. Inhibitors of NF-κB and P2X7/NLRP3/Caspase 1 pathway in microglia: novel therapeutic opportunities in neuroinflammation induced early-stage Alzheimer's disease. J Neuroimmunol. 2019;326:62–74. https://doi.org/10.1016/j.jneuroim.2018.11.010.CrossRefPubMed

28.

Flores J, Noël A, Foveau B, Lynham J, Lecrux C, LeBlanc AC. Caspase-1 inhibition alleviates cognitive impairment and neuropathology in an Alzheimer's disease mouse model. Nat Commun. 2018;9(1):3916. https://doi.org/10.1038/s41467-018-06449-x.CrossRefPubMedPubMedCentral

Title: Caspase-1 variant influencing CSF tau and FDG PET levels in non-demented elders from the ADNI cohort
Authors: Yi Liu
Meng-Shan Tan
Zuo-Teng Wang
Wei Xu
Lan Tan
Publication date: 01-12-2022
Publisher: BioMed Central
Keywords: Alzheimer's Disease
Alzheimer's Disease
Pathology
Mild Neurocognitive Disorder
Biomarkers
Published in: BMC Neurology / Issue 1/2022
Electronic ISSN: 1471-2377
DOI: https://doi.org/10.1186/s12883-022-02582-9

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Caspase-1 variant influencing CSF tau and FDG PET levels in non-demented elders from the ADNI cohort

Abstract

Background

Methods

Results

Conclusions

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2022

Correction: Perampanel as first add-on antiseizure medication: Italian consensus clinical practice statements

Safety and efficacy comparison between OACs plus single antiplatelet and dual antiplatelet therapy in patients with cerebral venous sinus stenosis poststenting

Cerebral venous sinus thrombosis caused by traumatic brain injury complicating thyroid storm: a case report and discussion

Correction: Palliative sedation in amyotrophic lateral sclerosis: results of a nationwide survey among neurologists and palliative care practitioners in Germany

Limits on using the clock drawing test as a measure to evaluate patients with neurological disorders

Comparison of outcomes between intracapsular resection and pseudocapsule-based extracapsular resection for pituitary adenoma: a systematic review and meta-analysis